Shots:China’s NMPA has accepted IND application for RN1871 for hypertension, with Rona planning to advance it in P-I trial to assess its safety, PK, & preliminary efficacy in humansPreclinical studies have demonstrated AGT suppression & sustained blood pressure control, with reduced dosing frequency of RN1871RN1871 is engineered to suppress AGT mRNA expression in the…
